Patient medication of pomalyst 2MG, 3MNG, 4MG. To be shipped to the baltimore VA medical center.
Ended Awarded Last action
- Contract number
- 36C24526N0553
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $138,603
Award facts
- Contract value 100% obligated
- $138,603.09 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer, has been awarded a delivery order by the Department of Veterans Affairs' Veterans Integrated Service Network 5 for the supply of Pomalyst (pomalidomide) in 2mg, 3mg, and 4mg formulations to support the Baltimore VA Medical Center. The contract is valued at $138,603.09 on a firm fixed-price basis with a completion date of May 4, 2026. This award represents a call against Bristol-Myers Squibb's existing Federal Supply Schedule contract (GSA Schedule 36F79724D0101) under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule, which carries a substantial ceiling value of $12.3 billion and extends through April 30, 2029. The delivery order carries no set-aside designations, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer.
Pomalyst is a specialty oncology pharmaceutical used in the treatment of hematologic malignancies, consistent with Bristol-Myers Squibb's core business focus on cancer therapies and immunotherapies. The product will be shipped from the company's manufacturing and distribution operations in Memphis, Tennessee. This delivery order is one of more than fifty issued by the Department of Veterans Affairs to Bristol-Myers Squibb since 2022, demonstrating sustained demand within the Veterans Health Administration for the company's advanced cancer treatment products to support the VA's mission of delivering state-of-the-art oncology care to eligible veterans across the federal healthcare system.
Quick answers
Who was awarded contract 36C24526N0553?
36C24526N0553 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on April 27, 2026.
How much is contract 36C24526N0553 worth?
The government has obligated $138,603 on 36C24526N0553.
Is contract 36C24526N0553 an order under another contract?
Yes. 36C24526N0553 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0553 competed?
The extent of competition for 36C24526N0553 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award